Live Analyst Rating Changes 1527 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Charles Rhyee
TD
Charles Rhyee
Wall Street Analyst
★★★☆☆
#864
on 13Foresight · ranked by our own returns
70%
Success Rate
+0.9%
Average Return
28 of 40 calls profitable · -84.6% vs benchmark
📈 Across the calls we could measure, roughly 70% of Charles Rhyee's ratings turned a profit when each position was held for 1 year — averaging +0.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

115 Buy 42 Hold 3 Sell
Charles's Stock Coverage 39 ratings · 2026-06-21
Company Date Position Consensus Price Target 1-Yr Return
BTSG
BrightSpring Health Services, Inc.
Jun 18, 2026 BUY Strong Buy
-16.3% avg upside
18 analysts
$81.00
22.27% Upside
·
MCK
McKesson
Jun 18, 2026 BUY Strong Buy
-2.2% avg upside
27 analysts
$1012.00
34.89% Upside
·
VEEV
Veeva Systems
Jun 04, 2026 BUY Strong Buy
+54.2% avg upside
36 analysts
$235.00
53.23% Upside
-5.5%
CRL
Charles River Labs
Jun 04, 2026 BUY Strong Buy
+11.9% avg upside
34 analysts
$235.00
27.08% Upside
-2.4%
COR
Cencora
Jun 01, 2026 BUY Buy
+14.6% avg upside
43 analysts
$400.00
47.18% Upside
+4.7%
ICLR
Icon
Jun 01, 2026 BUY Strong Buy
+23.8% avg upside
25 analysts
$164.00
12.42% Upside
+3.8%
MDRX
Veradigm
May 27, 2026 BUY Buy
+207.0% avg upside
22 analysts
$8.00
66.67% Upside
·
DRIO
DarioHealth
May 13, 2026 HOLD Strong Buy
+22.7% avg upside
5 analysts
$11.00
58.70% Upside
+3.5%
EVH
Evolent Health
May 11, 2026 BUY Strong Buy
+123.4% avg upside
19 analysts
$8.00
78.21% Upside
+6.6%
GDRX
GoodRx Holdings
May 11, 2026 BUY Buy
+387.4% avg upside
28 analysts
$4.00
50.34% Upside
-8.1%
CVS
CVS Health
May 11, 2026 BUY Strong Buy
+3.2% avg upside
38 analysts
$110.00
11.87% Upside
+6.6%
MDLN
Medline
May 07, 2026 BUY Strong Buy
+42.9% avg upside
26 analysts
$53.00
47.51% Upside
-14.1%
AMWL
American Well
May 06, 2026 HOLD Hold
+64.6% avg upside
15 analysts
$8.00
5.11% Downside
+5.0%
FTRE
Fortrea Holdings Inc.
May 05, 2026 BUY Buy
-3.5% avg upside
11 analysts
$18.00
17.48% Upside
-7.6%
IQV
IQVIA Holdings
May 05, 2026 BUY Strong Buy
+34.5% avg upside
38 analysts
$213.00
26.90% Upside
+1.1%
CI
Cigna
May 04, 2026 BUY Strong Buy
+24.2% avg upside
29 analysts
$338.00
21.03% Upside
+2.6%
WAY
Waystar Holding Corp.
May 04, 2026 BUY Strong Buy
+105.7% avg upside
29 analysts
$42.00
127.34% Upside
-11.8%
TDOC
Teladoc
May 04, 2026 HOLD Buy
+256.9% avg upside
37 analysts
$6.00
25.68% Downside
+6.9%
CAH
Cardinal Health
May 01, 2026 BUY Strong Buy
-12.7% avg upside
29 analysts
$255.00
14.91% Upside
+15.9%
OPCH
Option Care Health
Apr 30, 2026 HOLD Strong Buy
+34.7% avg upside
20 analysts
$23.00
4.51% Upside
+6.8%
MEDP
Medpace Holdings
Apr 23, 2026 HOLD Buy
-12.1% avg upside
16 analysts
$419.00
8.94% Downside
+17.0%
TALK
Talkspace
Feb 20, 2026 BUY Buy
-13.1% avg upside
12 analysts
$9.00
72.81% Upside
+4.2%
OWLT
Owlet
Nov 13, 2025 BUY Strong Buy
+142.2% avg upside
10 analysts
$15.00
200.05% Upside
-52.5%
KMPR
Kemper
Jun 11, 2025 BUY Buy
+161.7% avg upside
8 analysts
$90.00
259.56% Upside
-59.8%
W
Wayfair
Jun 05, 2025 BUY Buy
+24.0% avg upside
54 analysts
$51.00
42.47% Downside
+52.2%
XNCR
Xencor
Sep 09, 2024 BUY Buy
+159.9% avg upside
27 analysts
-58.2%
HLTHQ
Cue Health
Mar 15, 2024 HOLD Hold
2 analysts
-100.0%
CVX
Chevron
Oct 30, 2023 BUY Strong Buy
+7.0% avg upside
43 analysts
$170.00
2.08% Downside
+5.7%
BTTX
Better Therapeutics
Dec 12, 2022 BUY Strong Buy
+1499899.9% avg upside
3 analysts
·
MDVLQ
MedAvail Holdings
Aug 16, 2022 BUY Strong Buy
+224999900.0% avg upside
2 analysts
$250.00
249999899.98% Upside
·
OTRKQ
Ontrak
May 17, 2022 SELL Buy
+21716566.7% avg upside
7 analysts
$1.30
1299899.97% Upside
·
UNH
UnitedHealth
Apr 16, 2021 BUY Strong Buy
+2.3% avg upside
35 analysts
$415.00
3.49% Upside
+38.6%
ELV
Elevance Health
Apr 14, 2021 BUY Strong Buy
+10.9% avg upside
32 analysts
$395.00
1.69% Upside
+43.6%
OSCR
Oscar Health
Mar 29, 2021 HOLD Buy
-34.1% avg upside
15 analysts
$29.00
2.16% Upside
-59.7%
CNC
Centene
Feb 08, 2021 BUY Buy
+8.6% avg upside
28 analysts
$80.00
31.18% Upside
+47.1%
HUM
Humana
Feb 01, 2021 HOLD Buy
-11.2% avg upside
34 analysts
$460.00
27.50% Upside
+3.5%
MOH
Molina Healthcare
Jun 16, 2020 BUY Buy
+13.8% avg upside
25 analysts
$210.00
7.45% Upside
+40.9%
OMCL
Omnicell
Oct 30, 2015 HOLD Strong Buy
+35.7% avg upside
12 analysts
$29.00
25.78% Downside
+19.9%
ATHM
AutoHome
Feb 25, 2014 BUY Buy
+72.6% avg upside
15 analysts
$42.00
132.11% Upside
+7.4%
🔒 34 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Charles Rhyee — Frequently Asked Questions
How accurate are Charles Rhyee's stock ratings?
Based on the calls 13Foresight could measure, about 70% of Charles's ratings were profitable over a one-year hold, with an average return of +0.9% per rating, or -138.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Charles ranked on 13Foresight?
Charles Rhyee is currently ranked #864 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Charles cover?
Charles most recently has ratings on BTSG, MCK, VEEV, CRL, COR, ICLR, MDRX, DRIO, EVH, GDRX, CVS, MDLN and 27 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.